/Surgical Management of Heart Failure/ 4-u1.0-B978-1-4377-0398-6..00031-7..DOCPDF Chapter 31 4-u1.0-B978-1-4377-0398-6..00031-7 4-u1.0-B978-1-4377-0398-6..00031-7 4-u1.0-B978-1-4377-0398-6..00031-7--s0050 Surgical Management of Heart Failure Part IV 4-u1.0-B978-1-4377-0398-6..00031-7--s0010 Heart Failure hubpart 3 section Heart Failure Part IV 4-u1.0-B978-1-4377-0398-6..00031-7 4-u1.0-B978-1-4377-0398-6..00031-7--s0010 Surgical Management of Heart Failure 4-u1.0-B978-1-4377-0398-6..C2009-0-59734-6--p9 Surgical Management of Heart Failure text/html; charset=ISO-8859-1 Coronary Artery Revascularization Chapter 31 chapter bookContent 4-u1.0-B978-1-4377-0398-6..C2009-0-59734-6--p9 Coronary Artery Revascularization 4-u1.0-B978-1-4377-0398-6..00031-7 4-u1.0-B978-1-4377-0398-6..C2009-0-59734-6--p9 4-u1.0-B978-1-4377-0398-6..00031-7 4-u1.0-B978-1-4377-0398-6..00030-5--fr0010 5 4-u1.0-B978-1-4377-0398-6..00031-7--s0010 Chapter 31 Braunwald's Heart Disease, 9th edition 978-1-4377-0398-6 Bonow 1st
Chapter 31 – Surgical Management of Heart FailureMichael A. Acker,
Mariell Jessup
| | | CORONARY ARTERY REVASCULARIZATION, 601| | | Ischemic Cardiomyopathy, 601
| | | | Selection of Patients for Coronary Artery Revascularization, 601
| | | | Risks of Coronary Artery Bypass Grafting, 601
| | | | Benefits of Coronary Artery Bypass Grafting, 602
|
|
| | | VALVE SURGERY IN PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION, 603| | | Mitral Valve, 603
| | | | Aortic Valve, 606
|
|
| | | LEFT VENTRICULAR RECONSTRUCTION, 606
|
| | | PASSIVE CARDIAC SUPPORT DEVICES, 607
|
| | | CARDIAC TRANSPLANTATION, 608| | | Donor Allocation System, 608
| | | | Evaluation of the Potential Recipient, 608
| | | | The Cardiac Donor, 610
| | | | Surgical Considerations, 610
| | | | Immunosuppression, 611
| | | | Rejection, 611
| | | | Infection, 612
| | | | Medical Complications and Comorbidities, 613
| | | | Outcomes After Heart Transplantation, 614
|
|
| | | FUTURE PERSPECTIVES, 615
|
| | | REFERENCES, 615
|
In the current era of managing patients with heart failure with a depressed ejection fraction, clinicians frequently encounter optimally treated patients who remain symptomatic. Indeed, despite the variety of …